vTv Therapeutics logo
vTv Therapeutics
VTVT | NASDAQ
Chart Builder DCF Calculator
$17.69
-$2.00 (-10.16%)
At close: Nov 16, 2026, 4:00 PM ET
$17.69
$0.00 (0.00%)
After-hours: Nov 16, 2026, 4:10 PM ET

vTv Therapeutics Company Profile

Company profile explained

Company Profile

vTv Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on creating orally administered treatments, with a significant emphasis on diabetes. Its pipeline features lead candidates such as TTP399, an oral, small-molecule, liver-specific glucokinase activator targeting Type 1 diabetes. Another key investigational drug is HPP737, an oral phosphodiesterase type 4 (PDE4) inhibitor that does not cross the blood-brain barrier (non-CNS penetrant), designed to treat inflammatory conditions and psoriasis. Beyond these, vTv Therapeutics' broader clinical portfolio includes: TTP273, an oral small-molecule GLP-1 receptor agonist addressing postprandial glucose excursions in cystic fibrosis-related diabetes. HPP3033, which employs a non-electrophilic strategy to activate the Nrf2 pathway for chronic conditions linked to oxidative stress. Azeliragon, a RAGE antagonist being evaluated for inflammatory lung disorders, notably severe COVID-19, alongside pancreatic and breast cancers. HPP971, an Nrf2 activator aimed at renal diseases, developed in collaboration with pharmaceutical partners. Furthermore, vTv holds a licensing agreement with Reneo Pharmaceuticals, Inc. for the development and commercialization of its peroxisome proliferation-activated receptor delta agonist program, which features the compound HPP593. The company has also established various other licensing and research collaborations with entities such as Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., Newsoara Biopharma Co., Ltd., JDRF International, and Novo Nordisk A/S. Established in 2015, vTv Therapeutics is headquartered in High Point, North Carolina, and operates as a subsidiary of MacAndrews & Forbes Incorporated.

Key Executives

Name Position
Paul J. Sekhri Chief Executive Officer, President & Chairman of the Board
Michael Steven Tung Executive Vice President & Chief Financial Officer
Barry Brown Chief Accounting Officer
Carmen Valcarce Chief Scientific Officer & Executive Vice President
Elizabeth Keiley Executive Vice President & General Counsel
Martin Lafontaine Chief Commercial Officer
Richard S. Nelson Executive Vice President of Corporate Development & Director
Thomas Strack Chief Medical Officer

Latest SEC Filings

Date Type Title
Oct 08, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Oct 06, 2026 8-K Current Report
Aug 06, 2026 10-Q Quarterly Report
Aug 06, 2026 8-K Current Report
Jul 29, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Jun 29, 2026 4 Filing
Jun 29, 2026 8-K Current Report
Jun 29, 2026 4 Filing
Jun 29, 2026 4 Filing
Jun 29, 2026 4 Filing
View All SEC Filings ➞
vTv Therapeutics
vTv Therapeutics logo
Country United States
IPO Date Jul 30, 2015
Industry Biotechnology
Sector Healthcare
Employees 26
CEO Paul J. Sekhri

Contact Details

3980 Premier Drive High Point, North Carolina 27265 United States

Stock Details

Ticker Symbol VTVT
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001641489
CUSIP Number 918385204
ISIN Number US9183852048
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.